stockrow
Saturday 7 November 2026
Export NNVC’s income statement to Excel — free account
NanoViricides, Inc.
NNVC Healthcare Biotechnology
- EPS
- +23.1%
- Free cash flow
- −23.9%
Quarter to June 2026, against a year earlier
1.33
0.04
+3.10%
Follow NNVC
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | 77 | 77 | 134 | +32.1% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.0 pt | ||||||
| EBT | (10) | (9) | (8) | (13) | (9) | (8) | (9) | (8) | (9) | (8) | (2.5%) | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (10) | (9) | (8) | (13) | (9) | (8) | (9) | (8) | (9) | (8) | (2.5%) | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (3.40) | (2.60) | (2.40) | (2.39) | (0.81) | (0.70) | (0.74) | (0.70) | (0.63) | (0.41) | (20.9%) | ||||||
| Cash flow | (2.63) | (2.40) | (1.89) | (1.19) | (0.75) | (0.51) | (0.49) | (0.53) | (0.56) | (0.38) | (19.3%) | ||||||
| Capex | (0.05) | (0.07) | (0.02) | 0.00 | (0.02) | (0.03) | (0.01) | (0.01) | 0.00 | 0.00 | (24.8%) | ||||||
| Free cash flow | (2.68) | (2.47) | (1.92) | (1.19) | (0.78) | (0.54) | (0.50) | (0.55) | (0.56) | (0.39) | (19.4%) | ||||||
| Book value | 6.76 | 5.44 | 2.95 | 3.87 | 2.74 | 2.00 | 1.28 | 0.97 | 0.50 | 0.43 | (26.4%) | ||||||
| Shares, m | 3 | 3 | 4 | 6 | 11 | 12 | 12 | 12 | 15 | 20 | +23.6% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | (8) | (8) | (7) | (7) | (8) | (6) | (6) | (6) | (8) | (8) | (0.3%) | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (7.2%) | ||||||
| Free cash flow | (8) | (8) | (7) | (7) | (8) | (6) | (6) | (6) | (9) | (8) | (0.4%) | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | 11 | 6 | 0 | 12 | 20 | 14 | 8 | 4 | 0 | 2 | (17.1%) | |||||
| Net debt | (11) | (7) | (3) | (14) | (20) | (14) | (8) | (5) | (2) | (3) | (14.2%) | ||||||
| Shareholders’ equity | 20 | 18 | 11 | 22 | 30 | 23 | 15 | 11 | 8 | 9 | (9.0%) | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | (32.39) | (37.60) | (52.66) | (71.98) | (32.57) | (30.16) | (42.52) | (55.81) | (87.47) | (87.91) | (55.5) pt | |||||
| ROIC | (65.37) | (55.07) | (67.27) | (61.61) | (57.59) | (55.66) | (83.23) | (79.84) | (100.60) | (88.16) | (22.8) pt | ||||||
| ROE | (47.53) | (45.10) | (59.62) | (83.11) | (34.15) | (30.60) | (45.27) | (63.00) | (99.75) | (101.46) | (53.9) pt | ||||||
| People | |||||||||||||||||
| People | Employees | 7 | 7 | 17 | 17 | 17 | 17 | 7 | 7 | 7 | 7 | 0.0% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 2 Nov 2026
NanoViricides, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TVGN Tevogen Inc. | $36.2M | — (loss-making) | — | — | n/m | +5.78% (above 0%: growing) | — | 0.00% | Compare |
| PTHS Pelthos Therapeutics Inc. | $35.6M | — (loss-making) | — (loss-making) | — | n/m | −1,614.99% (below 0%: shrinking) | 76.86% | (111.02%) | Compare |
| VERU Veru Inc. | $35.1M | — (loss-making) | — (loss-making) | +99.23% (above 0%: growing) | n/m | +0.27% (above 0%: growing) | 67.84% | 0.00% | Compare |
| LIANY LianBio Sponsored ADR | $34.2M | 0.0× | — | — | n/m | +1,107.59% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GRDX GridAI Technologies Corp. | $33.3M | — (loss-making) | — | — | n/m | −2,640.98% (below 0%: shrinking) | (42.49%) | (15,258.21%) | Compare |
| NNVC NanoViricides, Inc. | $32.9M | — (loss-making) | — | — | n/m | −23.94% (below 0%: shrinking) | 0.00% | 0.00% | |
| PMN Promis Neurosciences | $32.7M | — (loss-making) | — | 0.00% | n/m | −169.46% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| INMB INmune Bio, Inc. | $32.6M | — (loss-making) | — (loss-making) | +8.70% (above 0%: growing) | n/m | +55.39% (above 0%: growing) | 100.00% | 0.00% | Compare |
| EYPT EyePoint, Inc. | $30.7M | — (loss-making) | — (loss-making) | −90.49% (below 0%: shrinking) | n/m | +0.41% (above 0%: growing) | 100.00% | (19,207.10%) | Compare |
| Median of peers | $33.7M | — | — | +4.35% | — | +0.34% | 67.84% | 0.00% |